Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-blind, Randomized, Controlled, Phase II Study to Evaluate Immunogenicity and Safety of Two Doses of the MVA-nef HIV Vaccine in HIV-1 Infected Patients With CD4 > 250/µl

NCT00189930 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT00189930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00189930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-blind, Randomized, Controlled, Phase II Study to Evaluate Immunogenicity and Safety of Two Doses of the MVA-nef HIV Vaccine in HIV-1 Infected Patients With CD4 > 250/µl
Lead sponsor
Bavarian Nordic
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2005
Completion date
December 31, 2006
Enrollment
77 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection